These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 19683638

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.
    Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R.
    N Engl J Med; 1999 Mar 04; 340(9):677-84. PubMed ID: 10053176
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.
    BMJ; 2014 May 27; 348():g3318. PubMed ID: 24868083
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure.
    Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y, Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP).
    Hypertens Res; 2012 Nov 27; 35(11):1102-10. PubMed ID: 22895063
    [Abstract] [Full Text] [Related]

  • 12. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
    Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.
    Lancet; 2008 Sep 27; 372(9644):1174-83. PubMed ID: 18757085
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.
    Ayala DE, Hermida RC, Mojón A, Fernández JR.
    Chronobiol Int; 2013 Mar 27; 30(1-2):340-52. PubMed ID: 23077973
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
    Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR.
    N Engl J Med; 2008 Oct 09; 359(15):1565-76. PubMed ID: 18784091
    [Abstract] [Full Text] [Related]

  • 15. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN, Devereux RB, Okin PM.
    J Electrocardiol; 2014 Oct 09; 47(5):630-5. PubMed ID: 25052475
    [Abstract] [Full Text] [Related]

  • 16. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.
    Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C.
    Lancet Neurol; 2009 Jan 09; 8(1):48-56. PubMed ID: 19058760
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, Wang DW, Qiao L, Xing L, Ren G, Zhao C, Yang R, Yuan Z, Wang C, Shi C, Liu S, Miao W, Li G, Chen CS, Sun Y, CRHCP Study Group.
    Lancet; 2023 Mar 18; 401(10380):928-938. PubMed ID: 36871573
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 18; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 19. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, Lu J, Li X, Gao Y, Lei L, Liu J, Li J, ESPRIT Collaborative Group.
    Lancet; 2024 Jul 20; 404(10449):245-255. PubMed ID: 38945140
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.